S. 723 · 118th Congress · Health
Access to Prescription Digital Therapeutics Act of 2023
- IntroducedMar 8, 2023 Done
- CommitteeDied Jan 3, 2025 Stopped here
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.
Congressional Research Service · summary of “Introduced in Senate” version · Mar 8, 2023
Who lobbies on it
3 organizations · 22 filings · Q1 2023–Q4 2024One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Boehringer Ingelheim Usa Corporation
7 of 8 quarters
“Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)”
$4.5M lobbying spend in 2024, all issuesQ4 2024 filing
-
Consumer Technology Association
4 of 8 quarters
“H.R. 4189/S.2016, CONNECT for Health Act of 2023 H.R. 4093, Remote Opioid Monitoring Act of 2023 H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023 H.R.1843/S.1001, Telehealth Expansion Act of 2023 H.R. 3875, Expanded Telehealth Access Act H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act…”
$5.0M lobbying spend in 2024, all issuesQ4 2024 filing
-
Otsuka America Pharmaceutical, Inc.
4 of 8 quarters
“Access to Prescription Digital Therapeutics Act (S.723/HR 1458). Due Process Continuity of Care Act (S. 971). Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low income subsidy beneficiaries.”
$1.2M lobbying spend in 2023, all issuesQ4 2023 filing
Organizations that named S. 723 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Mar 8, 2023Read twice and referred to the Committee on Finance.
- Mar 8, 2023Introduced in Senate